MARKET

ALPN

ALPN

Alpine Immune Sc
NASDAQ
39.64
+0.99
+2.56%
After Hours: 39.00 -0.64 -1.61% 18:20 03/28 EDT
OPEN
38.65
PREV CLOSE
38.65
HIGH
41.04
LOW
37.18
VOLUME
1.46M
TURNOVER
0
52 WEEK HIGH
42.88
52 WEEK LOW
6.40
MARKET CAP
2.60B
P/E (TTM)
-61.5815
1D
5D
1M
3M
1Y
5Y
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
NASDAQ · 21h ago
Weekly Report: what happened at ALPN last week (0318-0322)?
Weekly Report · 3d ago
Alpine Immune Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/21 15:35
Alpine Immune Sciences Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 03/21 15:35
HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Maintains $50 Price Target
Benzinga · 03/21 15:24
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
Alpine Immune Sciences, Inc. Presented new translational data for povetacicept at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024. The Company is a leading clinical-stage immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases. PovetACicept is a dual antagonist of the BAFF and APRIL.
Barchart · 03/21 06:45
Buy Rating Affirmed for Alpine Immune Sciences Amid Positive Povetacicept Trials and Strong Clinical Outlook
TipRanks · 03/21 06:16
Alpine Immune Sciences’ Growth at Risk: Navigating FDA and SEC Disruptions Amidst Political and Health Uncertainties
TipRanks · 03/21 06:02
More
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Webull offers Alpine Immune Sciences Inc stock information, including NASDAQ: ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.